Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop

Inclusion Criteria

• Have ankle dorsiflexion range of motion greater than or equal to neutral when assessed concurrent with test stimulation in sitting and standing and demonstrate adequate ankle and knee stability during gait at the time of screening
• Have had at least one stroke of any etiology (e.g., ischemic, hemorrhagic,etc.) experienced greater than or equal to 3 months prior to study enrollment, as confirmed by independent medical records, and result in drop foot sufficient to require prior or current prescription for and/or use of an AFO
• Have adequate cognition and communication abilities for informed consent, training and instructions, use of the L300, and provide feedback, to be demonstrated by either the subjects scoring greater than or equal to 24 (out of a possible 30) on the Mini Mental State Examination, or having a competent caregiver for these purposes
• Must be 18 years or older
• Have the ability to safely walk at least 10-meters with a maximum of 1 person assist
• Have a self-selected 10-meter gait speed of less than or equal to 0.8m/s at the time of assessment
• Have inadequate dorsiflexion/limb clearance or unable to achieve normal heel strike on ambulation without AFO
• Be medically stable

Exclusion Criteria

• Have fixed ankle contracture at greater than or equal to 5 degrees of plantar flexion in the hemiplegic leg with the knee extended
• Have excessive pain in the affected leg, as measured by a score greater than or equal to 4 on a 10-point visual analog scale
• Participation, within the past 3 months, currently, or during the course of the study in any interventional clinical studies without the Sponsor's approval
• Have a demand-type cardiac pacemaker, defibrillator, or any electrical or metallic implant
• Have a lower motor neuron disease or injury with inadequate response to stimulation
• Have significant swelling/edema in the leg extending up to the knee
• Have a history of chronic skin problems/conditions or cancerous lesion present or suspected in close proximity ot the expected site for L300 stimulation
• Are pregnant or plan on becoming pregnant in the next 45 weeks
• Have had botulinum toxin(type a or b) to the hemiplegic leg or arm within the past six weeks or plan to have botulinum toxin treatments during the course of the study
• Expectation of a significant change in the subject's spasticity medications during the course of the study for the effected leg
• Have unstable seizure disorder (average of greater or equal to 2 seizures per month)
• Have a pre-existing significant orthopedic conditions that are, a that investigator's discretion, determined as likely to limit ambulatory progress (e.g., total hip replacement [non-metallic], total knee replacement [non-metallic], limited lower extremity (LE) range of motion (ROM), rheumatoid arthritis, osteoarthritis, or other fracture or dislocation that underlies the expected site for L300 stimulation)
• Have a complete hemisensory loss ipsilateral to foot drop
• Used the L300 or other FES device for foot drop (e.g., Odstock Drop Foot System (ODFS), WalkAide by Innovation Neurotronics, etc.) for greater than or equal to 3 hours within the last 6 months prior to study enrollment
• Have major post-stroke depression (PHQ-9 greater than or equal to 10) that is not medically managed with antidepression medication and/or psychotherapy
• Currently or planning on participating in a neuro-rehabilitation physical therapy (PT) or occupational therapy (OT) program or new independent exercise programs with enrolled in the study. However, injury or a change in condition requiring PT or OT that would not affect gait outcomes maybe assessed by an off-site study committee, on a case-by-case basis